IL17A and cancer: PD-1 blockade promotes a Th1/Th17 response via enhanced production of interferon γ, interleukin (IL)-2, tumor necrosis factor-α, IL-6, and IL-17 and reduction of Th2 cytokine profiles in patients with cancer.4